These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
595 related articles for article (PubMed ID: 27909995)
41. Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4. Jenkins SG; Brown SD; Farrell DJ Ann Clin Microbiol Antimicrob; 2008 Jan; 7():1. PubMed ID: 18190701 [TBL] [Abstract][Full Text] [Related]
42. Antimicrobial characterisation of solithromycin (CEM-101), a novel fluoroketolide: activity against staphylococci and enterococci. Putnam SD; Sader HS; Farrell DJ; Biedenbach DJ; Castanheira M Int J Antimicrob Agents; 2011 Jan; 37(1):39-45. PubMed ID: 21075602 [TBL] [Abstract][Full Text] [Related]
43. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin. Felmingham D J Infect; 2002 Feb; 44 Suppl A():3-10. PubMed ID: 12150493 [TBL] [Abstract][Full Text] [Related]
44. International guidelines for the treatment of community-acquired pneumonia in adults: the role of macrolides. File TM; Tan JS Drugs; 2003; 63(2):181-205. PubMed ID: 12515565 [TBL] [Abstract][Full Text] [Related]
45. Activity of a novel series of acylides active against community-acquired respiratory pathogens. Pandya M; Chakrabarti A; Rathy S; Katoch R; Venkataraman R; Bhateja P; Mathur T; Kumar GR; Malhotra S; Rao M; Bhadauria T; Barman TK; Das B; Upadhyay D; Bhatnagar PK Int J Antimicrob Agents; 2010 Aug; 36(2):169-74. PubMed ID: 20493666 [TBL] [Abstract][Full Text] [Related]
46. Telithromycin: the first ketolide antimicrobial. Nguyen M; Chung EP Clin Ther; 2005 Aug; 27(8):1144-63. PubMed ID: 16199242 [TBL] [Abstract][Full Text] [Related]
47. Mechanisms, molecular and sero-epidemiology of antimicrobial resistance in bacterial respiratory pathogens isolated from Japanese children. Sunakawa K; Farrell DJ Ann Clin Microbiol Antimicrob; 2007 Aug; 6():7. PubMed ID: 17697316 [TBL] [Abstract][Full Text] [Related]
48. Activities of 16-membered ring macrolides and telithromycin against different genotypes of erythromycin-susceptible and erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae. Mazzariol A; Koncan R; Vitali LA; Cornaglia G J Antimicrob Chemother; 2007 Jun; 59(6):1171-6. PubMed ID: 17405779 [TBL] [Abstract][Full Text] [Related]
49. Treatment of Community-Acquired Pneumonia: A Focus on Lefamulin. Eraikhuemen N; Julien D; Kelly A; Lindsay T; Lazaridis D Infect Dis Ther; 2021 Mar; 10(1):149-163. PubMed ID: 33528794 [TBL] [Abstract][Full Text] [Related]
50. Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia. Biedenbach DJ; Farrell DJ; Flamm RK; Liverman LC; McIntyre G; Jones RN Int J Antimicrob Agents; 2012 Apr; 39(4):321-5. PubMed ID: 22306239 [TBL] [Abstract][Full Text] [Related]
51. Solithromycin in Children and Adolescents With Community-acquired Bacterial Pneumonia. Lang JE; Hornik CP; Elliott C; Silverstein A; Hornik C; Al-Uzri A; Bosheva M; Bradley JS; Borja-Tabora CFC; Di John D; Mendez Echevarria A; Ericson JE; Friedel D; Gonczi F; Isidro MGD; James LP; Kalocsai K; Koutroulis I; Laki I; Ong-Lim ALT; Nad M; Simon G; Syed S; Szabo E; Benjamin DK; Cohen-Wolkowiez M; Pediatr Infect Dis J; 2022 Jul; 41(7):556-562. PubMed ID: 35675525 [TBL] [Abstract][Full Text] [Related]
53. Efficacy and safety of telithromycin 800 mg once daily for 7 days in community-acquired pneumonia: an open-label, multicenter study. Fogarty CM; Patel TC; Dunbar LM; Leroy BP BMC Infect Dis; 2005 May; 5():43. PubMed ID: 15927060 [TBL] [Abstract][Full Text] [Related]
54. Microbiological profile of telithromycin, the first ketolide antimicrobial. Felmingham D Clin Microbiol Infect; 2001; 7 Suppl 3():2-10. PubMed ID: 11523558 [TBL] [Abstract][Full Text] [Related]
55. In vitro activity of solithromycin and its metabolites, CEM-214 and N-acetyl-CEM-101, against 100 clinical Ureaplasma spp. isolates compared with azithromycin. Furfaro LL; Spiller OB; Keelan JA; Payne MS Int J Antimicrob Agents; 2015 Sep; 46(3):319-24. PubMed ID: 26141231 [TBL] [Abstract][Full Text] [Related]
56. Comparative in vitro and bactericidal activities of telithromycin against penicillin-nonsusceptible, levofloxacin-resistant, and macrolide-resistant Streptococcus pneumoniae by time-kill methodology. Kays MB; Lisek CR; Denys GA Int J Antimicrob Agents; 2007 Mar; 29(3):289-94. PubMed ID: 17240118 [TBL] [Abstract][Full Text] [Related]
57. Antimicrobial susceptibility of Streptococcus pneumoniae isolates from vaccinated and non-vaccinated patients with a clinically confirmed diagnosis of community-acquired pneumonia in Belgium. Lismond A; Carbonnelle S; Verhaegen J; Schatt P; De Bel A; Jordens P; Jacobs F; Dediste A; Verschuren F; Huang TD; Tulkens PM; Glupczynski Y; Van Bambeke F Int J Antimicrob Agents; 2012 Mar; 39(3):208-16. PubMed ID: 22245497 [TBL] [Abstract][Full Text] [Related]
58. Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group. Patel T; Pearl J; Williams J; Haverstock D; Church D Respir Med; 2000 Feb; 94(2):97-105. PubMed ID: 10714413 [TBL] [Abstract][Full Text] [Related]
60. Telithromycin: the first ketolide for the treatment of respiratory infections. Kasbekar N; Acharya PS Am J Health Syst Pharm; 2005 May; 62(9):905-16. PubMed ID: 15851496 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]